Limited Visibility and Perception of the Clinical Relevance of Clopidogrel Pharmacogenetics in Cardiology Literature.

Citation analysis of CPIC/DPWG CYP2C19-clopidogrel guidelines in cardiology literature and clinical practice guidelines

Analysis of citations of CYP2C19-clopidogrel pharmacogenetic guidelines (CPIC, DPWG, UKCERSE) in cardiology literature reveals that only 3 of 19 analyzed cardiology guidelines/position statements reference these PGx guidelines. 58% of cardiology guidelines mention clopidogrel pharmacogenetics but conclude that preemptive CYP2C19 genotyping has limited clinical benefit — despite mounting evidence from RCTs and meta-analyses. This study quantifies the persistent gap between pharmacogenetic evidence and its integration into cardiology practice.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

This work documents a structural problem: cardiology guidelines ignore or downplay available pharmacogenetic evidence for clopidogrel, while RCT data demonstrate benefit from genotype-guided therapy. This resistance to PGx integration by organ specialists is a major barrier to real-world pharmacogenomics implementation — and an argument for cardiology-genetics collaborative models.

Clinical impact : 2/3 · Evidence strength : 2/3 · Novelty : 1/2 · Sample size : 1/1 · Journal quality : 1/1 → Total : 7/10